Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Claret Medical, Inc.

http://www.claretmedical.com

Latest From Claret Medical, Inc.

Can BlissBio’s HER2-Targeting ADC Challenge Enhertu In Breast Cancer?

A new deal worth up to $2bn-plus with Eisai has put Bliss Biopharmaceutical's HER2-targeting antibody-drug conjugate BB-1701 in the spotlight, as the global race heats up to find a possible challenger to Enhertu.

China Deals

Merck’s Keytruda And Seagen’s Padcev Become First PD-1/ADC Combo To Win US Approval

The blockbuster PD-1 inhibitor and antibody-drug conjugate will be used to treat a subset of first-line urothelial carcinoma patients considerably widening Padcev’s market, but rates of peripheral neuropathy with the combination have left some analysts concerned.

Approvals ImmunoOncology

A Closing Door? New China Leadership Takes Reins Amid Growth Anxiety

China's just-concluded National Congress elected new senior government leadership, but shifting top-level policy priorities and a worsening wider operating environment mean observers are worried about continued growth and ongoing pressures on drug pricing.

China Policy

Vera Pins Hopes On Per-Protocol Analysis To Revive Phase II IgAN Asset

The US firm is shifting its focus to IgAN after a promising new prespecified analysis of its Phase II trial of atacicept lifted hopes for the product’s prospects as compared with a key rival candidate.

Clinical Trials Renal
See All

Company Information

UsernamePublicRestriction

Register